Associated Papers
Identification of high-risk signatures and therapeutic targets through molecular characterization and immune profiling of TP53-mutant breast cancer.
Paulino PJIV et al.
Journal, Genetic Engineering & Biotechnology, 2025
41386839 (PubMed )
Supplement: mmc5.xlsx › Table_S2
Clinical Validation of a Rapid Automated Lymphoma Next-Generation Sequencing Panel.
Krigstein M et al.
Annals of Laboratory Medicine, 2025
41277019 (PubMed )
Supplement: ALM3692_Supple1.xlsx › Variant_Calls
TP53 Mutation Status in Myelodysplastic Neoplasm and Acute Myeloid Leukemia: Impact of Reclassification Based on the 5th WHO and International Consensus Classification Criteria: A Korean Multicenter Study.
Kim HY et al.
Annals of Laboratory Medicine, 2025
39497415 (PubMed )
Supplement: alm-45-2-160-supple.pdf
Follicular thyroid cancer harboring TERT and TP53 mutations: A case report.
Zhang J et al.
Asian Journal of Surgery, 2023
High-grade serous ovarian carcinoma organoids as models of chromosomal instability.
Vias M et al.
Elife, 2023
37166279 (PubMed )
Supplement: elife-83867-supp2.xlsx › Mutation_analysis
Different impacts of TP53 mutations on cell cycle-related gene expression among cancer types.
Sasaki K et al.
Scientific Reports, 2023
36964217 (PubMed )
Supplement: 41598_2023_32092_MOESM1_ESM.xlsx › Suppl._Table_S4
Select a paper to view details